181514-35-2

Basic information

• Product Name: 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE
• Synonyms: 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE;7-BROMO-N-TRIFLUOROACETYL-1,2,3,4-TETRAHYDROISOQUINOLINE;Ethanone, 1-(7-broMo-3,4-dihydro-2(1H)-isoquinolinyl)-2,2,2-trifluoro-;7-BroMo-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline, 98%;1-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one;1-(7-Bromo-3,4-dihydroisoquinolin-2(1H)
• CAS NO: 181514-35-2
• Molecular Formula: C₁₁H₉BrF₃NO
• Molecular Weight: 308.09
• Mol File: 181514-35-2.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE(181514-35-2)
• EPA Substance Registry System: 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE(181514-35-2)

Safety Data

• Hazardous Substances Data: 181514-35-2(Hazardous Substances Data)

Usage

General Description

1-(7-Bromo-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoroethanone is a chemical compound with the molecular formula C11H8BrF3NO. It is a synthetic organic compound that may be used in research and development or as an intermediate in the synthesis of other compounds. The presence of the bromine and fluorine atoms in the molecule gives it unique properties that make it suitable for use in specific chemical reactions or processes. 1-(7-BROMO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2,2,2-TRIFLUOROETHANONE may have potential applications in the pharmaceutical or agrochemical industries, and further study and experimentation could reveal its practical uses and benefits. However, it is important to handle and use this compound with caution due to its potential hazards and reactivity.

InChI:InChI=1S/C11H9BrF3NO/c12-9-2-1-7-3-4-16(6-8(7)5-9)10(17)11(13,14)15/h1-2,5H,3-4,6H2

Upstream product

• 50-00-0 formaldehyd 
• 181514-21-6 N-[2-(4-bromophenyl)ethyl]-2,2,2-trifluoroacetamide 
• 73918-56-6 4-Bromophenethylamine 
• 64-19-7 acetic acid 
• 407-25-0 trifluoroacetic anhydride 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 307301-10-6 7-(4-methylphenyl)-1,2,3,4-tetrahydroisoquinoline 
• 74291-57-9 2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl chloride 
• 253801-24-0 7-formyl-3,4-dihydroisoquinolin-2(1H)-carboxylic acid t-butyl ester 
• 1400648-43-2 2-[2-(4-tert-Butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide 
• 1400650-24-9 2-[2-(4-tert-butylphenyl)ethyl]-N-[2-fluoro-4-(hexyloxy)phenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

An efficient and convenient synthesis of acyl coa: Monoacylglycerol acyltransferase 2 inhibitor, 2-[2-(4-tert-butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide

An efficient and convenient synthesis of MGAT2 inhibitor, 2-[2-(4-tert-butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1,2,3, 4-tetrahydroisoquinoline-6-sulfonamide (1), is reported. The optimized route consists of an effective chlorosulfonylation and debromination, resulting in an increase in the total yield from 6.8% to 45%, compared with our previous method. This synthetic approach enabled the synthesis of 1 to be scaled-up to a multi-gram scale.

Pyrrolo pyrimidine ring compound, its use and pharmaceutical composition (by machine translation)

The invention relates to an as TLR7 agonist of the pyrrolo pyrimidine compounds, specifically on a compound of formula (I) compound or its pharmaceutically acceptable salt, preparation method thereof, containing the compounds of the pharmaceutical composition, and its use for the preparation of antiviral drug use. Formula (I) (by machine translation)